계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
Vedere Bio ll
company
About
Vedere Bio is developing gene therapy products to restore functional vision to patients who have suffered vision loss.
- 1 - 10
Highlights
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $77M
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jun 1, 2019
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Vedere is developing cutting-edge gene therapy products to restore functional vision to patients who have suffered vision loss from Inherited Retinal Degenerations (IRDs), as well as other causes of both genetic and non-genetic vision loss. While the vast majority of ocular gene therapies only limit the rate of inevitable vision loss, we aim to restore lost vision regardless of a patient’s underlying genetics or their stage of disease.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$98M
Vedere Bio ll has raised a total of
$98M
in funding over 2 rounds. Their latest funding was raised on
May 18, 2021 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 18, 2021 | Series A | $77M | 1 | — | — | Detail |
| Jun 1, 2019 | Series A | $21M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
Vedere Bio ll is funded by 2 investors.
Retinal Degeneration Fund
and Foundation Fighting Blindness
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Retinal Degeneration Fund
|
— | Series A |
Foundation Fighting Blindness
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
